U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Investor Presentation January 2020 :IN www.inmedpharma.com :IMLFF
Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company’s continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this presentation has been prepared in accordance with Canadian standards and is not comparable in all respects to similar information for United States companies. In addition, any financial information included in this presentation has been prepared in Canadian dollars, except as otherwise indicated, and is subject to applicable Canadian generally accepted accounting principles and Canadian auditing and auditor independence standards, which differ from United States generally accepted accounting principles and United States auditing and auditor independence standards in certain material respects. The information provided in this presentation is not intended to provide financial, tax, legal or accounting advice. The Company exists under the laws of the Province of British Columbia, Canada. A substantial portion of the Company’s assets are located outside the United States. As well, some of the Company’s officers and directors are residents of Canada. As a result, it may be difficult for investors to enforce civil liabilities under United States federal or state securities laws. 2
Disclaimers Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward - looking statements”) including, among others, statements concerning: unlocking the full potential o f cannabinoid pharmaceuticals; anticipated clinical development activities, timelines, catalysts, and milestones; the potential benefits of product candidates; anticipated revenue and market opportunities; the continued availability of key personnel; and a cash runway into 2H2020. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. With respect to the forward-looking information contained in this presentation, the Company has made numerous assumptions regarding, among other things: continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for the Company’s products; continued availability of key personnel; and continued economic and market stability. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described in the forward looking statements. These risks and uncertainties include, among others: the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results; risks associated with obtaining funding from third parties; risks related to the timing and costs of clinical trials; key personnel may become unable to serve the Company; the need for receipt of regulatory approvals; and economic and market conditions may worsen. Readers are cautioned that the foregoing list is not exhaustive. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s annual information form dated September 26, 2019, a copy of which i s available on SEDAR at www.sedar.com. The Company undertakes no obligation to update the forward looking statements contained herein or to reflect events or circumstances occurring after the date hereof, except as required by law. 3
A Differentiated Cannabinoid Pharmaceutical Company InMed is Focused on the Therapeutic Application of Cannabinoids for the Treatment of Diseases with High Unmet Medical Needs Researching the therapeutic potential of rare cannabinoids, beyond THC & CBD Selecting innovative, topically applied cannabinoid therapies for diseases with high unmet medical needs Developing a biosynthetic manufacturing approach that targets low cost production of biologically identical cannabinoids 4
The Medicinal Role of Cannabinoids <0.1% 2 – 5% 100+ Rare Cannabinoids Major Cannabinoids CBG, CBGA, CBGV, CBGVA, THCV, CBD THC THCA, THCVA, CBC, CBCV, CBCVA, CBDV, CBDA, CBC, CBCA, CBN, CBNA… • Epilepsy • Inflammation • The 100+ rare cannabinoids occur in • Anxiety • Nausea extremely low amounts in the cannabis plant • Stress • Stress • The cost of isolating sufficient Disorder Disorder quantities of these cannabinoids in • Pain • Sleep Apnea order to conduct research can be prohibitive Note: lists are not exhaustive 5
Proprietary Biosynthesis Process
Cannabinoid Manufacturing Alternatives Extraction from Plants Chemical Synthesis Biosynthesis • Plant – Grow – Harvest – Extract • Expensive for some, time – Purify process is resource consuming (weeks) for all intensive, large carbon Bio-identical to Extracts • Excessive chemical waste footprint, QA/QC issues • Problem of isomers (structural Cost Savings for Rare CBs • Expensive, takes months for a integrity) for some CBs that may single production batch Enhanced Purity and QC affect efficacy/safety; risk that • Pesticide removal is challenging, synthesized product may not be Pharma-grade CMC may result in import/export identical to the natural restrictions compounds Structural Integrity • Access to rare cannabinoids Advantage for some CBs prohibitively expensive 7
Biosynthesis: Completed R&D 2015 – 2016 2017 2018 Determined host Identified genetic elements Finalized plasmid design for system between bacteria needed to upregulate substrate cannabinoid production in E. coli and yeast concentration for cannabinoid production in E. coli Demonstrated target cannabinoid(s) production at laboratory scale USP – Up-stream Process (Fermentation); DSP – Down-stream Process (Purification); GMP – Good Manufacturing Practices; NRC – National Research Council of Canada; UBC - University of British Columbia (Vancouver); IRAP – Industrial Research Assistance Program; NSERC – Natural Sciences and Engineering Research Council; CDMO – Contract Development and Manufacturing Organization 8
Biosynthesis: High-level Time & Event Schedule 1H 2019 2H 2019 1H 2020 2H 2020 HPLC assay tech Finalize USP Scale-up for selected Conduct GMP transfer to NRC development at NRC cannabinoid at CDMO analytical assays #1; or development and Up-stream DSP development at process development fermentation tech CDMO #1/CDMO #2 Scale-up of alternative to support batch transfer to NRC process CDMO #2 production Conduct alternative Small scale bioreactor process studies Initiate GMP batch fermentation CDMO #2 production at CDMO if condition optimization needed Decision on future (on-going) manufacturing Filing of additional pathway patent applications Completed In Progress USP – Up-stream Process (Fermentation); DSP – Down-stream Process (Purification); GMP – Good Manufacturing Practices; NRC – National Research Council of Canada; CDMO – Contract Development and Manufacturing Organization 9
Biosynthesis: Competitive Landscape Bacteria Yeast Algae/Other • InMed strong IP position • Complicated IP landscape • Unproven scale-up process for pharma-grade API • Technically challenging but • Technically easier but less cost more cost effective for pharma- effective for pharma-grade API grade API BayMedica Hyasynth CB Therapeutics Librede Demetrix Willow (BioCan) Evolva BioTork Note: lists are not exhaustive 10
INM-755 for Epidermolysis Bullosa
INM-755: Epidermolysis Bullosa • Epidermolysis bullosa (EB) is a group of genetic conditions that cause the skin to be very fragile and to blister/rupture easily in response to minor injury or friction, such as rubbing or scratching • The most common form is EB Simplex (EBS), approx. 55% of all EB patients • No approved treatments specific to EB; treatment involves many products 12
INM-755: Epidermolysis Bullosa INM-755 is Being Investigated to Deliver Plan to further Evaluate IN-755 for Its Ability to Symptomatic Relief Via Multiple Potential Strengthen Skin (Reduce Frequency of Blistering) in a Mechanisms of Action in All EB Patients Sub-set of EBS Patients • Accelerated Wound Healing • Pain Reduction Dermal/ Epidermis Epidermal • Itch Reduction Junction Blister • Reduce Inflammation • [Antimicrobial Activity] Dermis 13
INM-755: Program Update Pharmacology • Data-to-date suggest that selected cannabinoid plays an important role in upregulating keratin 15 which may lead to strengthening skin in a subset of EBS patients, and may reduce inflammation and pain in all types of EB Toxicology • Completed 30+ studies with topical and subcutaneous dosing • Minimal systemic exposure following topical administration • Results of studies support planned clinical program Clinical and Regulatory • Selected CRO for two Ph1 clinical trials in Netherlands • Received CTA approval: 6 Dec 2019 • Study Site Initiation: 16 Dec 2019 14
Recommend
More recommend
